公开(公告)号：US20190125728A1

公开(公告)日：2019-05-02

申请号：US16089548

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei IKEDA ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: A61K31/4188 ,  A61K31/407 ,  A61K31/454 ,  A61K31/496 ,  A61P25/16 ,  A61P25/08 ,  A61P25/24 ,  A61P25/28 ,  A61P21/00

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20200255439A1

公开(公告)日：2020-08-13

申请号：US16651840

申请日：2018-09-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Makoto KAMATA ,  Hideyuki SUGIYAMA ,  Minoru NAKAMURA ,  Masataka MURAKAMI ,  Shuhei IKEDA ,  Tomohiro OKAWA ,  Hidekazu TOKUHARA

IPC: C07D487/10 ,  A61P25/28 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound having an MAGL inhibitory action, and expected to be useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

公开(公告)号：US20170362223A1

公开(公告)日：2017-12-21

申请号：US15538297

申请日：2015-12-21

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Eiji KIMURA ,  Yuhei MIYANOHANA ,  Masaki OGINO ,  Yuta TANAKA ,  Makoto FUSHIMI ,  Tomohiro OKAWA ,  Yuki HANYA ,  Tatsuki KOIKE

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61P25/00 ,  A61P29/00 ,  C07D487/04

Abstract: Provided is a compound having an antagonistic action on an NMDA receptor containing the NR2B subunit, and is useful as a prophylactic or therapeutic agent for major depression, bipolar disorder, migraine, pain, peripheral symptoms of dementia and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, (excluding N-(4-bromo-3-(1H-1,2,4-triazol-5-yl)thiophen-2-yl)-2-(imidazo[1,2-a]pyridin-5-yl)acetamide) or a salt thereof.

公开(公告)号：US20170283406A1

公开(公告)日：2017-10-05

申请号：US15474192

申请日：2017-03-30

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Shuhei Ikeda ,  Hideyuki SUGIYAMA ,  Jumpei AIDA ,  Hidekazu TOKUHARA ,  Tomohiro OKAWA ,  Yuya OGURO ,  Minoru NAKAMURA ,  Masataka MURAKAMI

IPC: C07D413/14 ,  C07D413/08 ,  C07D405/14 ,  C07D401/08

CPC classification number: C07D413/14 ,  C07D401/06 ,  C07D401/08 ,  C07D405/14 ,  C07D413/06 ,  C07D413/08

Abstract: The present invention provides a compound having an MAGL inhibitory action, and useful as an agent for the prophylaxis or treatment of neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, traumatic brain injury, glaucoma, multiple sclerosis etc.), anxiety disorder, pains (e.g., inflammatory pain, cancerous pain, neurogenic pain etc.), epilepsy, depression and the like.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20220098180A1

公开(公告)日：2022-03-31

申请号：US17426971

申请日：2020-01-29

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masahiro ITO ,  Takeshi YAMAMOTO ,  Keiko KAKEGAWA ,  Hideyuki SUGIYAMA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Osamu KUBO ,  Akinori TOITA ,  Takuto KOJIMA ,  Fumiaki KIKUCHI ,  Minoru SASAKI ,  Misaki HOMMA ,  Yasuhiro IMAEDA ,  Hironobu MAEZAKI ,  Shiinobu SASAKI ,  Ayumu SATO ,  Hirotaka KAMITANI ,  Yasutomi ASANO ,  Hironori KOKUBO ,  Masato YOSHIKAWA

IPC: C07D413/10 ,  C07D271/06 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.

公开(公告)号：US20210139491A1

公开(公告)日：2021-05-13

申请号：US16622632

申请日：2018-06-19

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Kazuaki TAKAMI ,  Masaki SETO ,  Shinobu SASAKI ,  Haruhi ANDO ,  Masaki OGINO ,  Tomoko OHASHI ,  Toshihiro IMAEDA ,  Ikuo FUJIMORI ,  Yasuhiro TSUKIMI ,  Masami YAMADA ,  Kenichiro SHIMOKAWA ,  Takeshi WAKABAYASHI ,  Masataka MURAKAMI ,  Makoto FUSHIMI ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Tomohiro OHASHI ,  Hideo SUZUKI ,  Hironobu MAEZAKI ,  Ayumu SATO ,  Yasutomi ASANO ,  Steve SWANN

IPC: C07D491/048 ,  A61K31/4355 ,  A61P1/10

Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20200039957A1

公开(公告)日：2020-02-06

申请号：US16499432

申请日：2018-03-29

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Seiji MIWATASHI ,  Yasufumi MIYAMOTO ,  Koji WATANABE ,  Yayoi NAKAYAMA ,  Yuko HITOMI ,  Jumpei AIDA ,  Nobuyuki TAKAKURA ,  Hideki FURUKAWA ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Kazuaki TAKAMI ,  Norihito TOKUNAGA ,  Tomohiro OKAWA ,  Akita SHIBUYA ,  Shizuo KASAl ,  Toshitake KOBAYASHI ,  Tsuyoshi MAEKAWA

IPC: C07D401/12 ,  C07D211/22 ,  C07D401/14 ,  C07C59/72 ,  C07D213/64 ,  C07D401/10 ,  C07D413/10

Abstract: Provided is a novel aromatic ring compound which may have a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof may have a GPR40 agonist activity and a GLP-1 secretagogue action, may be useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and may afford superior efficacy.

公开(公告)号：US20190135799A1

公开(公告)日：2019-05-09

申请号：US16049359

申请日：2018-07-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Masahiro ITO ,  Hideyuki SUGIYAMA ,  Osamu KUBO ,  Fumiaki KIKUCHI ,  Takeshi YASUI ,  Keiko KAKEGAWA ,  Zenichi IKEDA ,  Tohru MIYAZAKI ,  Yasuyoshi ARIKAWA ,  Tomohiro OKAWA ,  Jinichi YONEMORI ,  Akinori TOITA ,  Takuto KOJIMA ,  Yasutomi ASANO ,  Ayumu SATO ,  Hironobu MAEZAKI ,  Shinobu SASAKI ,  Hironori KOKUBO ,  Misaki HOMMA ,  Minoru SASAKI ,  Yasuhiro IMAEDA

IPC: C07D413/14 ,  C07D471/04 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61P25/28 ,  C07D413/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound.The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

公开(公告)号：US20160115128A1

公开(公告)日：2016-04-28

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei AIDA ,  Yayoi YOSHITOMI ,  Yuko HITOMI ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Hideki FURUKAWA ,  Akito SHIBUYA ,  Koji WATANABE ,  Yasufumi MIYAMOTO ,  Tomohiro OKAWA ,  Nobuyuki TAKAKURA ,  Seiji MIWATASHI

IPC: C07D211/34 ,  C07D413/10 ,  C07D401/14 ,  C07D405/12 ,  C07D413/14 ,  C07D401/10 ,  C07D401/12

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Abstract translation: 提供具有GPR40激动剂活性和GLP-1促分泌作用的新型芳环化合物。 由下式表示的化合物：其中每个符号如说明书所述，或其盐具有GPR40激动剂活性和GLP-1促分泌素作用，可用于预防或治疗癌症，肥胖症，糖尿病，高血压， 高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症等，具有优异的疗效。